Accelerating the Development and Practical Application of Anti-Infective Antibodies
Monoclonal antibodies (mAbs) have revolutionized the treatment of autoimmune diseases and cancer in the last two decades. Lately, an increasing number of mAbs are also being developed which are directly targeted against viruses and bacteria. These anti-infective mAbs have unique attributes that make them promising agents for novel treatment and prevention strategies against a broad spectrum of viruses and bacteria. However, physicians often lack experience with this new class of drugs, which hampers a broader clinical application.